KDR and neoplasm: Different targeting drugs were used in the experimental and control groups, but apatinib is a small molecule targeting drug against VEGFR-2, which blocks downstream signal transduction by highly selective competition for the ATP binding site of VEGFR-2 (also known as FLK-1), inhibits tyrosine kinase production thereby inhibiting neoangiogenesis in tumor tissue, and finally achieves the purpose of tumor treatment (53).